Urology · Troy, MI
NPI
1992760979
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
130 Town Center Dr, Suite 101
Troy, MI, 48084
Phone (248) 740-0670
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
25,165 services
Medicare patients, 2024
1,631
Average age 76
Drug cost, 2024
$3.1M
6,028 prescriptions
Company payments, 2025
$102K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth M Kernen was code J0897 (injection, denosumab, 1 mg), 7,500 times for 19 patients. In total Kenneth M Kernen billed 25,165 services in 100 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 7,500 | 19 | $20.64 | $155K |
| 81003 Clinical Chemistry | Office | 1,851 | 1,153 | $2.20 | $4,066 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,803 | 1,246 | $12.07 | $22K |
| 99214 Office E&M - Established | Office | 1,740 | 1,145 | $90.26 | $157K |
| 84153 Clinical Chemistry | Office | 966 | 723 | $18.02 | $17K |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 627 | 322 | $35.25 | $22K |
| 84154 Clinical Chemistry | Office | 531 | 449 | $18.02 | $9,569 |
| 84403 Clinical Chemistry | Office | 447 | 294 | $25.29 | $11K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 444 | 82 | $49.79 | $22K |
| 99213 Office E&M - Established | Office | 395 | 364 | $64.85 | $26K |
| 84402 Clinical Chemistry | Office | 392 | 276 | $24.96 | $9,784 |
| 84270 Clinical Chemistry | Office | 392 | 276 | $21.30 | $8,350 |
| 82040 Clinical Chemistry | Office | 391 | 275 | $4.85 | $1,896 |
| 80048 Clinical Chemistry | Office | 262 | 225 | $8.29 | $2,172 |
| 51798 Ultrasound - Nonspecific | Office | 248 | 192 | $8.83 | $2,190 |
By year: 2022 $1.2M for 25,484 services; 2023 $964K for 27,299 services; 2024 $1.1M for 25,165 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,851 | 1,153 | $2.20 | $4,066 |
| 84153 Clinical Chemistry | 966 | 723 | $18.02 | $17K |
| 84154 Clinical Chemistry | 531 | 449 | $18.02 | $9,569 |
| 84403 Clinical Chemistry | 447 | 294 | $25.29 | $11K |
| 84270 Clinical Chemistry | 392 | 276 | $21.30 | $8,350 |
| 84402 Clinical Chemistry | 392 | 276 | $24.96 | $9,784 |
| 82040 Clinical Chemistry | 391 | 275 | $4.85 | $1,896 |
| 80048 Clinical Chemistry | 262 | 225 | $8.29 | $2,172 |
| 80076 Clinical Chemistry | 53 | 37 | $8.01 | $425 |
| 85025 Blood Count | 46 | 33 | $7.61 | $350 |
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth M Kernen prescribed most often to Medicare patients was Finasteride, with 1,893 prescriptions and refills. In total Kenneth M Kernen wrote 6,028 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Finasteride Generic | 1,893 | 5,293 | 592 | $36K |
| Tamsulosin Hcl Generic | 1,012 | 2,688 | 349 | $23K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 411 | 1,134 | 130 | $13K |
| Dutasteride Generic | 411 | 1,134 | 135 | $19K |
| Tolterodine Tartrate Generic | 324 | 896 | 137 | $29K |
| Cephalexin Generic | 151 | 194 | 116 | $1,911 |
| Tadalafil Generic | 135 | 202 | 25 | $3,367 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 120 | 153 | 80 | $3,191 |
| Gemtesa Vibegron | 116 | 268 | 41 | $122K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 110 | 128 | 76 | $600 |
| Ciprofloxacin Hcl Generic | 107 | 126 | 67 | $821 |
| Xtandi Enzalutamide | 107 | 107 | 18 | $1.4M |
| Testosterone Generic | 107 | 128 | 24 | $11K |
| Myrbetriq Mirabegron | 98 | 248 | 38 | $108K |
| Orgovyx Relugolix | 92 | 92 | 15 | $233K |
Brand drugs: - claims; generic drugs: 5,432 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth M Kernen $102K ($102K in general payments such as food, travel and fees) from 23 companies. The largest payer was Janssen Biotech, Inc. with $32K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 31 | $32K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $18K |
| Sumitomo Pharma America, Inc. 4506.T | 25 | $18K |
| Dendreon Pharmaceuticals LLC | 19 | $12K |
| Astellas Pharma US Inc 4503.T | 8 | $9,691 |
| Siemens Medical Solutions USA, Inc. SHL.DE | 2 | $6,053 |
| Astellas Pharma Global Development 4503.T | 1 | $2,100 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,856 |
| Janssen Scientific Affairs, LLC JNJ | 3 | $1,247 |
| Olympus America Inc. | 18 | $189 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.